IGF2BP3 and lung adenocarcinoma: Although our results confirm that IGF2BP3 is a key driver of lung adenocarcinoma progression and a potential therapeutic target, its role needs to be elucidated in the context of other genes that have been clearly identified as having prognostic or therapeutic significance in LUAD.